UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 11, 2021

 

Integrity Health Corporation

(Exact name of registrant as specified in its charter)

 

Delaware 1-11765 22-3283541
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

 

2376 E Camelback Rd, Suite 600, Phoenix, AZ 85016

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: 602-806-9292

 

 

For The Earth Corporation

20 E. Thomas Road, Suite 2200, Phoenix, AZ 85012

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common FTEG OTC PINK 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

     

 

  

Cautionary Language Concerning Forward-Looking Statements

 

This Current Report on Form 8-K/A (this “Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Integrity Health Corporation’s reports that it files from time to time with the Securities and Exchange Commission (“SEC”) and which you should review, including those statements under “Item 1A – Risk Factors” in the Integrity Health Corporation’s Annual Report on Form 10-K, as may be amended, supplemented or superseded from time to time by other reports Integrity Health Corporation files with the SEC.

 

These forward-looking statements should not be relied upon as predictions of future events, and Integrity Health Corporation cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Integrity Health Corporation or any other person that Integrity Health Corporation will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. Integrity Health Corporation. disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this Report or to reflect the occurrence of unanticipated events, except as required by law.

 

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

On July 28, 2021, Integrity Health Corporation, (the “Company”), acquired all of the issued and outstanding membership interests of Medical Aesthetics Solutions, LLC d/b/a Point Lumineux Med Spa (“Point Lumineux Med Spa”) from Lea Graf. Point Lumineux Med Spa offers a wide range of cosmetic services, including everything from nutritional counseling to CoolSculpting®. The acquisition was consummated on July 28, 2021 pursuant to a Sale of LLC Interest Agreement (“Purchase Agreement”) dated as of July 28, 2021, by and among the Company and Lea Graf. The purchase price consisted of 150,000.00 in cash, subject to certain adjustments as provided in the Purchase Agreement to increase the purchase price to $250,000.00. As a result of the acquisition, Point Lumineux Med Spa became a wholly-owned subsidiary of the Company.

 

The pro forma financial information included in this Report has been presented for informational purposes only and is not necessarily indicative of the combined financial position or results of operations that would have been realized had the acquisition of Point Lumineux Med Spa occurred as of the dates indicated, nor is it meant to be indicative of any anticipated combined financial position or future results of operations that the Company will achieve after the acquisition.

 

Item 9.01 Financial Statements and Exhibits.

 

(a) Financial Statements of Business Acquired.

 

The audited financial statements and related notes thereto of Point Lumineux Med Spa as of and for the year ended December 31, 2020, including the related audit report of the independent auditors, Urish, Popeck & Co, LLC.

  

(d) Exhibits

 

Exhibit Number   Description
2.1   Sale of LLC Interest Agreement dated as of July 28, 2021, by and among the Integrity Health Corp. and Lea Graf.
     
2.2   Addendum to the Sale of LLC Interest Agreement, dated as of July 28, 2021, by and among the Integrity Health Corp., Sera Balderston and Lea Graf.
     
99.1   The audited financial statements and related notes thereto of Medical Aesthetics Solutions, LLC d/b/a Point Lumineux Med Spa as of and for the year ended December 31, 2020, including the related audit report of the independent auditors, Urish, Popeck & Co, LLC.

 

 

 

 

  2  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Integrity Health Corporation
   
   
  By /s/ NELSON GRIST
   

Name: NELSON GRIST

Title: PRESIDENT & CEO

Date: August 11, 2021

 

 

 

 

 

 

 

 

  3  

 

Exhibit 2.1

 

SALE OF LLC INTEREST AGREEMENT

 

THIS SALE OF LLC INTEREST AGREEMENT (this "Agreement") is dated as of July 28, 2021 (the "Effective Date"), and is made and entered into by and between Integrity Health Corporation, a Delaware corporation ("Buyer") and Lea Graf ("Seller"), in connection with Seller's sale of all of her interests in Medical Aesthetic Solutions, LLC, a Florida limited liability company, d/b/a Point Lumineux Med Spa (the "Company") to Buyer.

 

A. Seller is the beneficial and record owner of 100% of the membership interests in the Company.

 

B. Seller desires to sell to Buyer and Buyer desires to purchase from Seller all of Seller's membership interest in the Company (the "Seller's Interest") on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, for and in consideration of the mutual covenants and conditions herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

ARTICLE I

SALE AND PURCHASE

 

1.1 Sale and Purchase of Seller's Interest. This Agreement is intended to be signed and closed on the same date herein called the "Effective Date." On the Effective Date, Seller shall sell, assign, and transfer to Buyer all of the Seller's Interest in the Company, and Buyer shall purchase, acquire, and accept the Seller's Interest from Seller, all upon the terms and conditions set forth in this Agreement.

 

1.2 Purchase Price. The purchase price for the Seller's Interest is One Hundred and Fifty Thousand Dollars ($150,000.00) (the "Purchase Price") with an option for the Seller to earn an additional $100,000 to be added onto the Purchase Price subject to the terms and conditions as outlined herein.

 

1.3 Payment of the Purchase Price.

 

1.3.1 Payment. On the Effective Date, Buyer shall deliver to Seller, by wire transfer, a payment for Buyer's first equity payment in the amount of One Hundred and Fifty Thousand Dollars ($150,000) ("First Payment").

 

1.3.2 On or before December 31, 2021, contingent on the conditions being met as outlined in the addendum attached hereto and Section 4.2 herein, Buyer shall deliver to Seller, by wire transfer, an additional payment in the amount of Fifty Thousand Dollars as long as there is no interference, negative comments about the MedSpa or employees or any type of harassment towards the employees of the MedSpa ($50,000) by Seller and/or Sera Balderston ("Second Payment").

 

1.3.3 On or before April 1, 2022, contingent on the conditions being met as outlined in the addendum attached hereto and Section 4.2 herein, Buyer shall deliver to Seller, by wire transfer, an additional payment in the amount of Fifty Thousand Dollars ($50,000) as long as there is no interference, negative comments about the MedSpa or employees or any type of harassment towards the employees of the MedSpa by Seller and/or Sera Balderston ("Third Payment").

 

ARTICLE II

REPRESENTATIONS, WARRANTIES AND COVENANTS OF SELLER

 

Seller hereby represents and warrants to Buyer, and covenants with Buyer, as follows:

 

2.1 Authority and Capacity . The Company is a limited liability company duly organized, validly existing, and in good standing under the laws of the State of Florida and has all requisite power, authority and capacity to enter into this Agreement and to perform its obligations hereunder and to consummate the transactions contemplated hereby. No approval or consent of any persons other that Seller is necessary.

 

 

 

  1  

 

 

2.2 Agreement Will Not Cause Breach or Violation. The execution, delivery and performance of this Agreement by Seller does not and the consummation of the transaction contemplated hereby will not (a) conflict with any provision of Company's charter documents; (b) result in a breach of or default under any other agreement to which Seller or the Company is a party or by which they are bound; or (c) violate any law applicable to the Company or any judgment, order, injunction, decree or award of any court, arbitrator, administrative agency or governmental body applicable to or binding upon the Company.

 

2.3 Binding Agreement. This Agreement has been duly and validly executed and delivered by Seller and constitutes Seller's valid and binding agreement, enforceable against Seller in accordance with and subject to its terms.

 

2.4 Title to Seller's Interest. Seller is the lawful record and beneficial owner of all of Seller's Interest, free and clear of any liens, claims, agreements, charges, security interests and encumbrances whatsoever. On the Effective Date, the Operating Agreement of the Company showing ownership of the membership interests of the Company shall be amended to memorialize this transaction and to show that Buyer owns 100% of the membership interests in the Company, subject to the terms of this Agreement. Seller shall sign such documents and provide such certificates as may be required to evidence the sale of Seller's Interest.

 

2.5 Absence of Liabilities. Except for the items listed on Exhibit A, to the actual knowledge of Seller, without duty of inquiry or investigation, there are no material debts, liabilities or obligations of any nature, whether accrued, absolute, contingent, or otherwise, that are not reflected on the Company's balance sheet.

 

2.6 Compliance with Laws. Except for the items list on Exhibit B, to the actual knowledge of Seller, the Company has not received notice that it is in violation of any applicable federal, state, or local statute, law, ordinance, or regulation affecting the operation of the Company's business.

 

2.7 Absence of Litigation. Except for the items listed on Exhibit B, to the actual knowledge of Seller, the Company has not received notice of any pending or threatened suit, action, arbitration, or legal or administrative proceeding or investigation affecting the Company or its business.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer hereby represents and warrants to Seller as follows:

 

3.1 Authority and Capacity of Buyer; No Default of Company. Buyer has all requisite power, authority and legal capacity to enter into this Agreement and to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by Buyer does not and the consummation of the transaction contemplated hereby will not (a) conflict with any provision of the Buyer's charter documents; (b) result in a breach of or default under any other agreement to which the Buyer is a party or by which either is bound; or (c) violate any law applicable to Buyer, or any judgment, order, injunction, decree or award of any court, arbitrator, administrative agency or governmental body applicable to or binding upon Buyer.

 

3.2 Binding Agreement. This Agreement has been duly and validly executed and delivered by Buyer and constitutes Buyer's valid and binding agreement, enforceable against Buyer in accordance with and subject to its terms.

 

ARTICLE IV
COVENANTS

 

4.1 Conduct of Business of the Company. Seller covenant that, prior to the Effective Date, Seller shall cause the Company to:

 

(a) Conduct its business only in the ordinary and usual course and will not incur any debts or liabilities other than in the ordinary course;

 

 

 

  2  

 

 

(b) Not do or cause to be done anything that would cause any of Sellers' representations or warranties to be untrue or inaccurate if made at the time, except as otherwise permitted by this Agreement or consented to in writing by Buyer;

 

(c) Maintain its property, plant and equipment in accordance with good business practice;

 

(d) Use its best efforts to preserve its business organization intact, keep available the services of its present management, including, but not limited to Buyer, and preserve the goodwill of its suppliers, customers, and others having business relations with it; and

 

(e) Permit no distribution to be authorized or paid, nor any increase in the compensation payable or to become payable by it to any of its directors, managers, officers, managerial employees or consultants, or other employees.

 

4.2 Post-Closing Covenants. In consideration of the Purchase Price, and other good and valuable consideration, the sufficiency of which is hereby acknowledged, following the Closing hereof, and as a condition to complete said Closing, Sellers agree that they have information regarding the Company and will continue to be in a position of trust and confidence, having familiarity with the Company's operations, including, but not limited to financial and business information, client lists, bidding practices, tax records, unique production and/or service methods, proprietary information (including patents if any), employee benefits, personnel history, accounting procedures, surety limits or terms, bank lending terms, promotions, products, bid methods, strategies, goals, employees, consultants, equipment condition and capability, job status (executory and completed), technology, services, procedures, clients and services, bid processes, potential clients, potential service areas, and general operations of the Company (collectively "Confidential Information"). It is hereby acknowledged by all Parties that all the foregoing, both individually and combined, define the business of the Company, and are valuable, special, and unique assets of the Company and its business; the disclosure of or inappropriate use of these assets without the specific written authorization of the Company will cause serious harm to the business and good will of the Company, potentially causing significant monetary loss. Seller recognizes and acknowledges that the Company has taken reasonable steps to preserve and protect the secrecy of all of the foregoing confidential information and trade secrets.

 

(a)  Non-Disclosure. Seller shall keep all Company's Confidential Information and trade secrets, strictly confidential and Seller shall not disclose any of the Company's Confidential Information to any third party without the prior written consent of the Company or pursuant to an order of a court of competent jurisdiction.

 

(b)  Non-Solicitation. Commencing on the Effective Date, and continuing for a term of eighteen (18) months, Seller agrees not to (i) solicit, encourage or attempt to induce (or to assist others to do so) any employee or agent of the Company to terminate his or her employment or working relationship with the Company, or to work with such Seller (or any business, person or activity for profit in which such Seller is associated with) in any capacity whatsoever, or (ii) solicit, encourage, attempt to induce or otherwise contact any of the Company's existing or prospective customers or clients (known to Seller as of the Effective Date) (or to assist others to do so) for the purpose of reducing, restructuring or terminating its (or their) business relationship with the Company or to shill its business from the Company to any other provider of competing services or goods.

 

(c)  Non-Disparagement. Seller and Buyer mutually agree that they will make no written or oral statements that directly or indirectly disparage the Company, or each other, or their respective officers, directors, employees, agents or affiliates in any manner whatsoever, including, but not limited to the working conditions or employment practices of the Company.

 

(d)   Non-Interference. The Seller covenants and agrees that she will not at any time, for whatever reason, whether for her own account or for the account of any other person, firm, corporation or other business organization: (i) interfere with contractual relationships between the Company and any of its customers or employees; or (ii) interfere with the method by which the Buyer manages and controls the Company. Seller hereby agrees that the Second Payment and Third Payment are conditioned on Seller's compliance with this Section 4.2(d).

 

 

 

  3  

 

 

(e)  Remedies Include Injunctive Relief. In the event Seller breaches or threatens to breach the terms of this Section 4.2, in whole or in part, the Company shall be entitled to all remedies to which it may be entitled in law or in equity including injunctive relief, and monetary damages.

 

(f)  Addendum. The Parties and Sera Balderston shall sign that attached Addendum that is incorporated herein.

 

4.3 Notification of Transaction.. Buyer shall make such filings with the Securities and Exchange Commission as may be required in connection with this transaction. Buyer and Seller may make such public announcements (including, without limitation, press releases and announcements in trade and industry publications and publications of general interest) as each deems appropriate; provided, however, that such public announcements shall be subject to review and approval by the other party, to be granted or denied within three business days of request, with consent not to be unreasonably withheld and with silence being deemed consent. The parties shall reasonably cooperate with each other in making such announcements and filings.

 

4.4 Trademarks and Tradenames . As of the Effective Date, Seller shall assign to the Company, to the extent owned by Seller, without warranty, the sole and exclusive right to use the names "Point Lumineux Med Spa" and "Medical Aesthetic Solutions, LLC," and any similar name or forms thereof, and Seller shall have no right to use and of the foregoing names from and after the Effective Date.

 

4.5. Indemnification.

 

4.5.1 Indemnification by Buyer. Buyer will indemnify, defend, and hold Seller, and each of Seller's officers, directors, employees, and agents harmless from and pay any and all losses, costs, damages, claims, obligations, liabilities and expenses (including, without limitation, all reasonable attorneys' fees and costs), whether known or unknown, contingent or vested, matured or unmatured, and whether or not resulting from third-party claims (collectively, "Claims"), directly or indirectly resulting from, relating to, arising out of or attributable to any of the following: (a) any breach of any representation or warranty Buyer has made in this Agreement; or (b) any breach, violation or default by Buyer of any covenant, agreement or obligation of Buyer in this Agreement.

 

4.5.2 Indemnification by Seller. Seller shall indemnify, defend, and hold Buyer, and each of Buyer's members, officers, directors, employees, and agents harmless from and pay any and all losses, costs, damages, claims, obligations, liabilities and expenses (including, without limitation, all reasonable attorneys' fees and costs), whether known or unknown, contingent or vested, matured or unmatured, and whether or not resulting from third-party claims (collectively, "Claims"), directly or indirectly resulting from, relating to, arising out of or attributable to any of the following: (a) any breach of any representation or warranty Seller has made in this Agreement; (b) any breach, violation or default by Seller of any covenant, agreement or obligation of Seller in this Agreement; (c) any grossly negligent or willful misconduct of Seller in connection with the Company occurring prior to the Effective Date.

 

ARTICLE V

Conditions Precedent to the Obligations of Buyer to Close

 

The obligations of Buyer to close hereunder on the Closing Date are subject to the fulfillment at or prior to the Closing Date of each of the following conditions (any one or more of which may be waived in whole or in part by it in writing):

 

5.1 Representations and Warranties True and Correct. The representations and warranties of each Seller contained herein shall be true and correct in all material respects on the Closing Date with the same force and effect as though such representations and warranties had been made on and as of the Closing Date.

 

5.2 Performance of Covenants. Seller shall have performed and complied with all material terms, covenants, and conditions of this Agreement to be performed or complied with by each of them on or before the Closing Date.

 

5.3 No Material Adverse Change. No damage, destruction, or loss (whether or not covered by insurance) and no other event materially and adversely affecting the Company's assets, financial condition, or business prospects of the Company shall have occurred.

 

 

 

  4  

 

 

5.4 No Litigation. No action or proceeding shall have been instituted in which an order has been entered restraining or prohibiting or invalidating the transactions contemplated by this Agreement or affecting the right of Buyer to own the Units after the Closing Date, and no such action or proceeding shall have been threatened or instituted (whether or not such an order has been entered) by any governmental department or agency, except as shown on Exhibit "B."

 

ARTICLE V

MISCELLANEOUS

 

6.1 Entire Agreement. This Agreement constitutes the entire understanding and agreement of the parties relating to the subject matter hereof and supersedes any and all prior understandings, agreements, negotiations and discussions, both written and oral, between the parties hereto with respect to the subject matter hereof.

 

6.2 Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with, and shall be governed by, the laws of the State of Florida without reference to, and regardless of, any applicable choice or conflicts of laws principles.

 

6.3 Counterparts and Signatures. This Agreement may be executed in any number of counterparts and by the several parties hereto in separate counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same Agreement. Signatures by facsimile or electronic means shall be valid and enforceable.

 

6.4 Further Assurances. Each of the parties hereto shall from time to time at the request of the other party hereto, and without further consideration, execute and deliver to such other party such further instruments of assignment, transfer, conveyance and confirmation and take such other action as the other party may reasonably request in order to more effectively fulfill the purposes of this Agreement.

 

6.5 Severability. The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof. If any provision hereof is determined by a court of competent jurisdiction or an arbitrator to be invalid or unenforceable, such provision shall be limited to the extent necessary to make it valid and enforceable, or if necessary, severed from this Agreement, and the remainder of the Agreement shall be in full force and effect.

 

6.6 Attorneys' Fees. If either party brings a claim or lawsuit against the other party to this Agreement to interpret or enforce any of the terms of this Agreement, the prevailing party shall, in addition to all other damages, be entitled to reasonable attorneys' fees and costs, costs of witnesses, and costs of investigation from the non-prevailing party.

 

6.7 Amendment and Termination. This Agreement may be amended or terminated only upon a writing executed by both Buyer and Seller.

 

6.8 Successors and Assigns. Subject to the provisions of this Agreement relating to the transferability of Seller's Interest, this Agreement shall be binding upon and inure to the benefit of Buyer and Seller and their respective successors and assigns. Whenever appropriate in this Agreement, references to Buyer or Seller shall be deemed to refer to such company's successors or assigns.

 

6.9 Dispute Resolution.

 

6.9.1 Arbitration. All disputes concerning this Agreement shall be settled by arbitration, before one arbitrator, in accordance with the commercial arbitration rules of the American Arbitration Association then in effect. The arbitrator shall be selected in accordance with such commercial arbitration rules. A party is entitled to initiate an arbitration proceeding if a dispute cannot be resolved amicably within ten days after the other party has been notified of the existence of the dispute. The arbitrator is authorized to grant injunctive relief and/or specific performance in addition to monetary relief. The arbitrator hereby is instructed to interpret and enforce this Agreement in strict accordance with its terms, and in accordance with Florida law. All arbitration proceedings shall be held in Florida.

 

 

 

  5  

 

 

6.9.2 Equitable Relief. Notwithstanding the foregoing, each party is entitled to bring an action for temporary or preliminary injunctive relief at any time in any court of competent jurisdiction in order to prevent irreparable injury that might result from a breach of this Agreement. Furthermore, upon the occurrence of an event of default, Seller is entitled to exercise all of the rights and remedies described in this Agreement and, at any time, to bring an action in a court of competent jurisdiction (or, at its election, to initiate an arbitration proceeding) for purposes of enforcing the terms of this Agreement.

 

6.9.3 Award. The award of the arbitrator in any arbitration proceeding shall be final and may be enforced in any court of competent jurisdiction, and an action to compel arbitration may be brought in any court of competent jurisdiction. The unsuccessful party to any arbitration proceeding or to any court action that is permitted by this Agreement shall pay to the successful party all costs and expenses, including, without limitation, reasonable attorneys' fees and the fees of the arbitrator, incurred therein by the successful party. EACH PARTY AGREES THAT, TO THE EXTENT PERMISSIBLE BY LAW, ALL RIGHTS TO A TRIAL BY A JURY OF ANY CLAIM CONCERNING THIS AGREEMENT ARE ABSOLUTELY AND FOREVER WAIVED.

 

Executed as of the date first above written.

 

  Buyer:
   
  Integrity Health Corporation, Inc., a Delaware corporation
   
  By: /s/ Nelson Grist
         Nelson Grist
  Its: Chief Executive Officer
   
   
  Seller:
   
  By: /s/ Lea Graf
         Lea Graf
  Its: Sole Member of Medical
        Aesthetics Solutions, LLC
   
   
  Company:
   
  Medical Aesthetic Solutions, LLC., a Florida limited liability company
   
  By: /s/ Lea Graf
          Lea Graf
  Its Managing Member

 

 

 

  6  

 

 

EXHIBIT A

Medical Aesthetic Solutions, LLC

 

Balance Sheet

As of July 27, 2021

 

TOTAL
ASSETS  
Current Assets  
Bank Accounts  
BOA - Advantage Chk - (0680) 33,724.96
PayPal 39.63
Petty Cash 546.25
zPayments in Transit 4,904.57
Total Bank Accounts $39,215.41
   
Other Current Assets  
Cool Sculpting Prepaid Cards 22,650.00
Employee Advances 273.79
Mindbody Inventory 37,338.88
Total Other Current Assets $60,262.67
   
Total Current Assets $99,478.08
Fixed Assets  
Medical Equipment 102,231.12
xAccumulated Depreciation -89,904.00
Total Fixed Assets $12,327.12
TOTAL ASSETS $111,805.20
   
LIABILITIES AND EQUITY  
Liabilities  
Current Liabilities  
Accounts Payable  
Accounts Payable (A/P) 18,763.17
Total Accounts Payable $18,763.17
   
Credit Cards  
BoA CC Parent - 9447 6,890.65
Total Credit Cards $6,890.65
   
Other Current Liabilities  
Gift Cards - Liability 7,345.50
Sales Tax Payable 50.34
SBA PPP Loan 39,327.00
Total Other Current Liabilities $46,722.84
Total Current Liabilities $72,376.66
Long-Term Liabilities  
Loan from Shareholder 10,000.00
Zeltiq Note Payable 13,437.63
Total Long-Term Liabilities $23,437.63
Total Liabilities $9,814.29
 
Equity  
Common Stock 100.00

 

Accrual Basis Wednesday, July 28, 2021 02:44 PM GMT-04:00

 

  7  

 

 

Medical Aesthetic Solutions, LLC

 

Balance Sheet

As of July 27, 2021

 

  TOTAL

C

ontributions

37,201.74
Retained Earnings -1,412.60
Net Income -19,898.23
Total Equity $15,990.91
TOTAL LIABILITIES AND EQUITY $111,805.20

 

 

 

 

 

  8  

 

 

 

 

  9  

 

 

 

 

 

 

 

 

  10  

 

 

EXHIBIT B

 

COMPLIANCE WITH LAWS / LITIGATION

 

Medical Aesthetic Solutions LLC is disclosing that a disgruntled former employee reported fraudulent activity to CrimeStoppers, who then, in turn, reported to the Florida Department of Health. The report was related to Sera Balderston and Medical Aesthetic Solutions LLC and alleged that Sera Balderston performed services which were not allowed under her license. Sera Balderston is cooperating with the investigation and believes the report is incorrect as the services did not occur. Sera Balderston and her license will not be involved with Medical Aesthetic Solutions LLC after the closing of the sale.

 

This information has been fully disclosed to the Buyer, who has had sufficient time to fully investigate this matter.

 

 

 

  11  

 

Exhibit 2.2

 

ADDENDUM

 

THIS addendum (“Addendum”) is dated as of July 28, 2021 and is made and entered into by and between Integrity Health Corporation, a Delaware corporation (“Buyer”), Lea Graf and Sera Balderston, in connection with Lea Graf’s sale of all of her interests in Medical Aesthetic Solutions, LLC, a Florida limited liability company, d/b/a Point Lumineux Med Spa (the “Company”) to Buyer. In connection with the Sale of LLC Interest Agreement and as a condition precedent for the Second Payment and Third Payment as outlined in Section 1.3 of the Agreement, Lea Graf and Sera Balderston hereby warrant to Buyer that for 18 months post-closing:

 

1.                  Neither will interfere nor harass the Buyer, its employees, directors, affiliates, officers, directors, shareholders, members, managers, agents and assigns.

 

2.                  Post-closing, neither will interfere with the day-to-day operations or management of the Buyer’s business operations which shall then include Medical Aesthetic Solutions, LLC, a Florida limited liability company, d/b/a Point Lumineux Med Spa (or any other name that it may become known by as reflected by the Florida Secretary of State) or interfere with any customers, clients, or vendors of the Buyer.

 

3.                  The above-named parties understand and acknowledge that it is the current trend in society for persons to share their opinions of their dealings with others and to air their disputes and disagreements in online media, social media, online ratings, in person with friends, associates, or family members and/or internet or published complaint bureaus. The parties recognize and agree that such online social media and complaint bureaus do not always provide due process that is both fair and equitable to both parties, and that such are subject to abuse, distortion, misrepresentation, mistaken belief regarding the facts and applicable law, duress, unfair and prejudicial negotiation, and defamation. The parties shall not disparage each other, including their directors, officers, agents or employees or otherwise take any action which could reasonably be expected to adversely affect the other parties' personal or professional reputation and agree to refrain from the use of disparaging online media, social media or other online publication or rating as it relates to any party without the express written approval of the affected party.

 

4.                  Should a party breach the provisions of this Addendum, the other party shall be entitled to all available legal and equitable remedies, including but not limited to, temporary and permanent injunctive relief, plus damages and a forfeiture of the Second Payment or Third Payment as outlined in Section 1.3 of the Agreement.

 

5.                  Buyer understand and agrees that neither Lea Graf nor Sera Balderston will be employees or associated with the Company post-closing.

 

6.                  Sera Balderston further agrees to be bound by the terms and conditions of Section 4.2 inclusive of any subparts of the underlying Agreement.

 

This Addendum may be signed by facsimile or electronic means and both are valid and enforceable.

 

Date: 7/28/2021 Date: 7/28/2021
By: /s/ Lea Graf By: /s/ Sera Balderston
       Lea Graf        Sera Balderston
   
   
  Integrity Health Corporation, Inc., a Delaware corporation
   
  By: /s/ Nelson Grist
          Nelson Grist
  Its: Chief Executive Officer
   

 

Exhibit 99.1

 

Medical Aesthetic Solutions, LLC

 

Financial Statements

For the Period March 16, 2020 (Inception)

Through December 31, 2020

 

Table of Contents

 

 

Independent Auditors’ Report 2
   
   
Financial Statements  
   
Balance Sheet 3
   
Statement of Operations and Member’s Equity 4
   
Statement of Cash Flows 5
   
Notes to Financial Statements 6 - 10

 

 

 

 

 

 

  1  

 

 

Independent Auditor’s Report

 

To the Member of

Medical Aesthetic Solutions, LLC

 

 

We have audited the accompanying financial statements of Medical Aesthetic Solutions, LLC, which comprise the balance sheet as of December 31, 2020, and the related statement of income and cash flows for the period March 16, 2020 (inception) through December 31, 2020, and the related notes to the financial statements.

 

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

 

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

 

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

 

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

 

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Medical Aesthetic Solutions, LLC as of December 31, 2020, and the results of its operations and its cash flows for the period March 16, 2020 (inception) through December 31, 2020, in accordance with accounting principles generally accepted in the United States of America.

 

 

 

 

August 10, 2021

Pittsburgh, PA

 

 

  2  

 

 

MEDICAL AESTHETIC SOLUTIONS, LLC

BALANCE SHEET

December 31, 2020

     

 

December 31,   2020  
       
Assets        
         
Current assets        
Cash   $ 41,475  
Inventory     33,085  
Total current assets     74,560  
         
Equipment        
Medical equipment     89,904  
Less accumulated depreciation     (9,711 )
Net equipment     80,193  
         
Total assets   $ 154,753  
         
Liabilities and Member's Equity        
         
Current liabilities        
Accounts payable   $ 4,180  
Note payable     32,003  
Other current liabilities     13,669  
Total current liabilities     49,852  
         
Non-current liabilities        
Deferred income tax liability     16,841  
         
Member's equity     88,060  
         
Total liabilities and member's equity   $ 154,753  

 

The accompanying notes are an integral part of these financial statements.

 

 

  3  

 

 

MEDICAL AESTHETIC SOLUTIONS, LLC

STATEMENT OF OPERATIONS AND MEMBER'S EQUITY

March 16, 2020 (Inception) Through December 31, 2020

     

 

    March 16, 2020
(Inception) through
December 31, 2020
 
       
Revenue        
Service revenue   $ 507,466  
Product revenue     21,652  
Total revenue     529,118  
         
Cost of goods sold        
Purchases     108,556  
Salaries and wages     70,706  
Fees     12,222  
Depreciation     9,711  
Total cost of goods sold     201,195  
         
Gross profit     327,923  
         
Operating expenses        
Salaries and wages     54,352  
Advertising expense     62,341  
Rent expense     26,739  
Other operating expenses     74,452  
Total operating expenses     217,884  
         
Income from operations     110,039  
         
Other income (expense)        
Interest expense     (5,401 )
Other income     263  
Income before taxes     104,901  
Income tax expense     (16,841 )
Net income     88,060  
         
Member's equity        
Beginning of period      
End of period   $ 88,060  

 

The accompanying notes are an integral part of these financial statements.

 

 

 

  4  

 

 

MEDICAL AESTHETIC SOLUTIONS, LLC

STATEMENT OF CASH FLOWS

March 16, 2020 (Inception) Through December 31, 2020

 

       
    March 16, 2020
(Inception) through
December 31, 2020
 
       
Cash flows from operating activities        
Net income   $ 88,060  
Adjustments to reconcile net loss to net cash provided by operating activities:         
Depreciation     9,711  
Changes in operating assets and liabilities:        
Inventory     (11,807 )
Accounts payable and accrued expenses     17,849  
Deferred income tax liability     16,841  
Net cash provided by operating activities     120,654  
         
Cash flows from investing activities        
Purchase of equipment     (71,245 )
         
Cash flows from financing activities        
Proceeds from borrowings     (7,934 )
         
Net increase in cash     41,475  
         
Cash, beginning of period      
         
Cash, end of period   $ 41,475  
         
Non-cash operating and financing activities        
Inventory acquired through term loan   $ 21,278  
Equipment acquired through term loan   $ 18,659  
         
Supplemental disclosures of cash flow information        
Interest paid   $ 5,401  

 

The accompanying notes are an integral part of these financial statements.

 

 

 

  5  

 

 

Medical Aesthetic Solutions, LLC

 

Notes to Financial Statements

March 16, 2020 (Inception) Through December 31, 2020

 

 

1.      Summary of Significant Accounting Policies

 

Nature of Operations

 

Medical Aesthetic Solutions, LLC (the “Company”) was formed on March 16, 2020 (inception) under the laws of the State of Delaware to operate as a limited liability company. The Company is engaged in the business of providing outpatient medical services at its office in Sarasota, Florida. The organization, business and summary of significant accounting policies of the Company are presented to assist in understanding the accompanying financial statements. The financial statements and notes are those of the Company, and its management is responsible for their integrity and objectivity. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which, in the opinion of management, have been consistently applied.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could materially differ from those estimates.

 

Cash

 

Cash is maintained at a banking institution that are insured by the Federal Deposit Insurance Company up to $250,000.  The Company’s deposits may, from time to time, exceed the $250,000 limit; however, management believes that there is no unusual risk present, as the Company places its cash with financial institutions which management considers being of high quality.

 

Inventory

 

Inventory is stated at the lower of cost or net realizable value.  Cost is determined by the first-in-first-out method.

 

Equipment

 

Equipment is stated at cost less accumulated depreciation.  Depreciation is computed on the straight-line method over the estimated five-year useful life of the depreciable assets. The Company capitalizes equipment with a cost in excess of $2,500. Expenditures for maintenance and repairs are charged against operations.

 

 

 

  6  

 

 

Medical Aesthetic Solutions, LLC

 

Notes to Financial Statements

March 16, 2020 (Inception) Through December 31, 2020

 

 

1.      Summary of Significant Accounting Policies (cont.)

 

Revenue Recognition

 

At inception, the Company adopted FASB issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606).  ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance.

 

The guidance outlines a five-step process for revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards, and also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Major provisions include determining which goods and services are distinct and represent separate performance obligations, how variable consideration is recognized, whether revenue should be recognized at a point in time or over time and ensuring the time value of money is considered in the transaction price.

 

Revenue is recognized upon satisfaction of all contractual performance obligations and transfer of control to the customer and is measured as the amount of consideration the Company expects to be entitled to in exchange for corresponding goods or services. Substantially all of the Company's sales are single performance obligation arrangements. For service and product revenue, the transaction price is equivalent to the stated price of the product, net of any stated discounts at a point in time. Service and product revenue is recognized at the point of sale, net of sales tax.

 

Advertising

 

The Company expenses the costs of advertising as paid and totaled $62,341 for the period ended December 31, 2020.

 

Income Taxes

 

The Company is a limited liability company classified as a C Corporation for income tax purposes and is not currently under examination by any taxing jurisdiction.

 

The Company accounts for income taxes in accordance with ASC 740-10, “Accounting for Income Taxes.” Under this accounting standard, deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using the applicable enacted income tax rates. Income tax expense includes federal currently payable and deferred taxes arising from temporary differences between taxable income for financial and income tax reporting purposes. These temporary differences result principally from depreciation.

 

The Company adopted ASC 740-10, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109.”  ASC 740-10 prescribes a minimum recognition threshold and measurement methodology that a tax position taken or expected to be taken in a tax return is required to meet before being recognized in the financial statements.

 

 

 

  7  

 

 

Medical Aesthetic Solutions, LLC

 

Notes to Financial Statements

March 16, 2020 (Inception) Through December 31, 2020

 

 

1.      Summary of Significant Accounting Policies (cont.)

 

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which will require entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. The ASU simplifies the current guidance, which requires entities to separately present Deferred Tax Assets (DTAs) and Deferred Tax Liabilities (DTLs) as current and noncurrent in a classified balance sheet. ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15, 2017, and early adoption is permitted. ASU 2015-17 may be either applied prospectively to all DTAs and DTLs or retrospectively to all periods presented. Management adopted ASU 2015-17 in your inception. As a result, all DTAs and DTLs are presented as noncurrent in the accompanying consolidated balance sheets as of December 31, 2020.

 

In accordance with ASC 740-10, management performed an analysis of the Company’s tax positions and concluded that there are no uncertain tax positions, therefore, a liability for unrecognized tax positions is not required.

 

The Company’s deferred income tax liability was $16,841 as of December 31, 2020. There were no other material deferred tax assets and liabilities.

 

Recent Accounting Pronouncements

 

ASU No. 2016-02, Leases (Topic 842). In February 2016, the FASB issued a new standard on leasing. From the lessee's perspective, the new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement for lessees. From the lessor's perspective, the new standard requires a lessor to classify leases as sales type, finance or operating. A lease will be treated as a sale if it transfers all of the risks and rewards, as well as control of the underlying asset, to the lessee. If risk and rewards are conveyed without the transfer of control, the lease is treated as a financing lease. If the lessor doesn't convey risks and rewards or control, an operating lease results. For nonpublic entities this new standard is effective for fiscal years beginning after December 15, 2021. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. A modified retrospective transition approach is required for lessors for sales-type, direct financing, and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of this new pronouncement on its financial statements.

 

 

 

 

  8  

 

 

Medical Aesthetic Solutions, LLC

 

Notes to Financial Statements

March 16, 2020 (Inception) Through December 31, 2020

 

 

2.      Equipment

 

Equipment is as follows at December 31:

 

December 31,   2020  
       
Medical equipment   $ 89,904  
Less accumulated depreciation     (9,711 )
         
Net equipment   $ 80,193  

 

Depreciation expense for the period ended December 31, 2020 was $9,711.

 

3.      Controlling Interest and Related Party Transactions

 

All of the Company’s membership units are owned by one individual.

 

4.      Facility Lease

 

The Company leases a retail facility under an operating lease on a month-to-month basis. The monthly lease payments are $3,390 and total rent expense was $26,739 for the period ended December 31, 2020.

 

5.      Note Payable

 

On July 1, 2020, the Company purchased inventory and equipment and assumed the loan related to the assets in the amount of $39,937. Annual interest on the loan is 9.482% and monthly payments are $2,667. The remaining term of the note as of the acquisition date was fourteen months. The entire outstanding balance of $32,003 is classified as a current liability as of December 31, 2020.

 

6.      Subsequent Events

 

Management has evaluated events and transactions subsequent to the balance sheet through the date of the independent auditors’ report (the date the financial statements were available to be issued) for potential recognition or disclosure in the financial statements. Management has not identified any items requiring recognition or disclosure, except as described below.

 

 

 

 

  9  

 

 

Medical Aesthetic Solutions, LLC

 

Notes to Financial Statements

March 16, 2020 (Inception) Through December 31, 2020

 

 

6.      Subsequent Events (cont.)

 

On May 19, 2021, the Company entered into a $39,327 loan agreement with Itria Ventures LLC that included terms and conditions related to the forgiveness of the loan and the guaranty by the U.S. Small Business Administration (“SBA”), an agency of the Government of the United States, under the Paycheck Protection Program.  Interest on the loan is charged at 1% and the maturity date is five years from the date of the loan.  The indebtedness may be forgiven, pursuant to and subject to, the terms of the Paycheck Protection Program (15 U.S.C. § 636(a)(36)), and the guidance issued in relation thereto by the SBA and/or the U.S. Department of Treasury.

 

On July 28, 2021, the sole member’s entire interest in the Company was sold to an unrelated third party.

 

 

 

 

 

 

 

 

 

  10